Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials

• DOI: 10.1111/dom.15620
• Publication Date: 2024-05-03T05:33:55Z
• Authors: Domenica Rubino; Jakob B. Bjorner; Naveen Rathor; Arya M. Sharma; Lisa von Huth Smith; Sean Wharton; Thomas Wadden; Niels Zeuthen; Ronette L. Kolotkin
• Keywords: Semaglutide; SF-36

Abstract Aims To summarize the effects of semaglutide 2.4 mg on weight‐related quality life (WRQOL) and health‐related (HRQOL), focusing confirmatory secondary endpoint physical functioning. Materials Methods The STEP 1–4 Phase 3a, 68‐week, double‐blind, randomized controlled trials assessed efficacy safety versus placebo in individuals with overweight/obesity. WRQOL HRQOL were by change from baseline to Week 68 two different but complementary measures, Impact Weight Quality Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT; 1 2) SF‐36v2 Health Survey Acute (SF‐36v2; 1–4). Results Superiority for over based IWQOL‐Lite‐CT functioning scores was confirmed 2 1, 4, respectively. At 68, a greater proportion participants treated than reached meaningful within‐person (MWPC) thresholds Physical Function (51.8% vs. 28.3%; p < 0.0001) (39.6% 29.5%; = 0.0083) MWPC threshold Functioning (39.8% 24.1%; 0.0001), (41.0% 27.3%; 4 (18.0% 6.6%; 0.0001). All other scale numerically improved placebo, except Role Emotional 2. Conclusions Semaglutide significantly functioning, proportions achieving compared showed beneficial beyond